PALISADE BIO, INC.
PALI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PALI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PALI
Palissade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, an orally administered PDE4 inhibitor, for inflammatory bowel disease indications including ulcerative colitis (UC) and Crohn's disease (CD).
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$348.5M
Cash Runway
49.6 moLead Asset
pali-2108 (Phase 1)
Next Catalyst
Phase2_Topline · Sep 30, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials · 2 catalysts for PALISADE BIO, INC..
Palissade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, an orally administered PDE4 inhibitor, for inflammatory bowel disease indications including ulcerative colitis (UC) and Crohn's disease (CD).
- Cash and cash equivalents of $125.2M as of June 30, 2026, with no significant contractual obligations [sec_mda · as of 2026-08-10].
- Net income of -$10.6M for the six months ended June 30, 2026, reflecting ongoing operating losses [sec_mda · as of 2026-08-10].
- Phase 2 ASCENTRA-UC trial for PALI-2108 in UC is ongoing, with a primary efficacy readout expected in the second half of 2027 [sec_mda · as of 2026-08-10].
- Phase 2 ASCENTRA-CD trial for PALI-2108 in CD is planned, with a primary efficacy readout expected in early 2028 [sec_mda · as of 2026-08-10].
- Company has not generated significant revenues and expects to incur substantial losses for the foreseeable future [sec_mda · as of 2026-08-10].
What works
- Cash position of $125.2M as of June 30, 2026, is expected to fund operations through key clinical milestones including the UC and CD readouts [sec_mda · as of 2026-08-10].
- No significant contractual obligations, providing financial flexibility [sec_mda · as of 2026-08-10].
- October 2025 Offering raised gross proceeds of $138M, significantly increasing working capital [sec_mda · as of 2025-11-10].
What to weigh
- Company has incurred significant operating losses and negative cash flows from operations since inception, with no revenues generated to date [sec_mda · as of 2026-08-10].
- Expects to incur substantial losses for the foreseeable future, with no path to profitability in the near term [sec_mda · as of 2026-08-10].
- Dependence on successful clinical development of PALI-2108; any delays or failures could require additional financing [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Cash and cash equivalents as of June 30, 2026
“cash and cash equivalents balance of $125.2 million as of June 30, 2026”
SEC MD&A · August 10, 2026
Phase 2 UC readout expected in second half of 2027
“primary efficacy readout of our Phase 2 ASCENTRA-UC clinical trial that is expected in the second half of 2027”
SEC MD&A · August 10, 2026
Phase 2 CD readout expected in early 2028
“primary efficacy readout of our planned ASCENTRA-CD clinical trial that is expected in early 2028”
SEC MD&A · August 10, 2026
No significant contractual obligations
“We currently have no significant contractual obligations.”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2026-09-30 · Phase2_Topline · pali-2108 — Phase 2 Readout: pali-2108 — First of two Phase 2 topline readouts for PALI-2108; results will inform efficacy and safety in UC.
- 2027-12-31 · Phase2_Topline · pali-2108 — Phase 2 Readout: pali-2108 — Second Phase 2 topline readout for PALI-2108; likely the ASCENTRA-UC primary efficacy readout.
Risks & what to watch (3)›
Key risks
- Clinical trial failure risk — PALI-2108 is in Phase 2; failure to meet endpoints could halt development and impair value [sec_mda · as of 2026-08-10].
- No revenue or profitability — Company has not generated significant revenues and expects continued losses; no near-term profitability [sec_mda · as of 2026-08-10].
- Dependence on financing — Future capital needs may require additional financing if operating plans change or milestones are delayed [sec_mda · as of 2026-08-10].
What to watch
- Phase 2 ASCENTRA-UC topline data for PALI-2108 expected in second half of 2027 [sec_mda · as of 2026-08-10].
- Initiation and enrollment of Phase 2 ASCENTRA-CD trial for PALI-2108 in Crohn's disease [sec_mda · as of 2026-08-10].
- Cash burn rate and any changes in liquidity position or financing needs [sec_mda · as of 2026-08-10].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run PALISADE BIO, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PALISADE BIO, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
49.6 months
D/E 0.05 · 0% dilution
Lead: Phase 1
1 candidate
2 upcoming, next in ~31d
6 buys · 2 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
93
Total value held
$246.6M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 21,378,904 | $37.5M |
| perceptive advisors llc | 17,856,298 | $31.2M |
| ameriprise financial inc | 8,711,385 | $15.2M |
| commodore capital lp | 7,181,062 | $12.6M |
| ra capital management, l.p. | 7,124,116 | $12.5M |
| franklin resources inc | 5,785,189 | $10.1M |
| goldman sachs group inc | 5,373,951 | $9.4M |
| boxer capital management, llc | 4,799,875 | $8.4M |
| morgan stanley | 4,551,533 | $8.0M |
| adage capital partners gp, l.l.c. | 4,500,000 | $7.9M |
Showing top 10 of 93 institutional holders of PALISADE BIO, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 15.6%
- Days to cover
- 5.2
- Shares short
- 26,147,446
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PALI short interestGovernance
Frequently asked questions
What is the AI investment thesis for PALISADE BIO, INC.?
Palissade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, an orally administered PDE4 inhibitor, for inflammatory bowel disease indications including ulcerative colitis (UC) and Crohn's disease (CD).
What is PALISADE BIO, INC.'s lead drug candidate?
PALISADE BIO, INC.'s most advanced tracked candidate is pali-2108 (Phase 1) for Fibrostenotic Crohn's Disease; Ulcerative Colitis (UC).
What is PALISADE BIO, INC.'s next catalyst?
PALISADE BIO, INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: pali-2108" — expected September 30, 2026.
Who is the CEO of PALISADE BIO, INC.?
Mr. J. D. Finley is the chief executive officer of PALISADE BIO, INC. (PALI).
Where is PALISADE BIO, INC. headquartered?
PALISADE BIO, INC. (PALI) is headquartered in Denver, CO, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.